Prothena Corp (PRTA) PT Lowered to $31 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
RBC Capital on Prothena Corp (PRTA), 'Today's Downside Move May Be Excessive'
September 30, 2024 1:03 PM EDTRBC Capital analyst Kennen MacKay reiterated a Sector Perform rating and $24.00 price target on Prothena Corp (NASDAQ: PRTA).
The analyst said: "Shares of PRTA are down ~20% today, likely on the announcement of the departure of their CMO late last Friday... More
Prothena Corp. (PRTA) Announces Leadership Team Updates
September 27, 2024 4:05 PM EDTProthena Corporation plc (NASDAQ: PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Chad Swanson, Ph.D., has been appointed Chief Development Officer and will assume leadership of clinical development and medical functions. Chad will join Prothenas executive leadership team and will report to Gene Kinney, Ph.D., President and Chief Executive Officer. Hideki Garren, M.D., Ph.D., will pursue an opportunity at a large pharmaceutical company to lead a global product development division. Prothena will initiate a search for... More
